Clinical features and outcome of multiple myeloma arising from the transformation of a monoclonal gammapathy of undertermined significance

Leukemia and Lymphoma

Volumn 34, Issue 5-6, 1999, Pages 591-596

  Patriarca, Francesca ^a   Fanin, Renato ^a   Silvestri, Federico ^a   Candoni, Anna ^a   Zaja, Francesco ^a   Sperotto, Alessandra ^a   Geromin, Antonella ^a   Baccarani, Michele ^a  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

Malignant transformation; MGUS; Multiple myeloma

Indexed keywords

BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; DEXAMETHASONE; DOXORUBICIN; IDARUBICIN; MELPHALAN; MITOXANTRONE; PREDNISONE; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; BONE LESION; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL FEATURE; FEMALE; FOLLOW UP; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PATIENT MONITORING; PLASMACYTOSIS; PRIORITY JOURNAL; PROGNOSIS; RISK; TREATMENT OUTCOME;

EID: 0032863477     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199909058488     Document Type: Article

References (12)

1. Kyle RA. (1982) Monoclonal gammapathy of undertermined significance (MGUS): a review. Clinical Haematology, 11, 123-150.
2. Van de Poel MUW, Coebergh JWW, Hillen HFP. (1995) Malignant transformation of MGUS among patients f a community hospital in Southeastern Netherland. British Journal of Haematology, 91, 121-125.
3. Greipp PR, Kyle RA. (1983) Clinical, morphological and cell kinetic differences among MM, MGUS and smoldering MM. Blood, 62, 166-170.
4. Boccadoro M, Garavatti P, Fossati G, Marmont F, Neretto G, Gallomini A, Volta C, Tribalto M, Testa MG, Amadori S, Mandelli F, Dune BGM. (1984) Low plasma cell 3(H) thymidine incorporation in MGUS, smoldering myeloma and remission phase myeloma : a reliable indicator of patients not requiring therapy. British Journal of Haematology, 58, 689.
5. Isaksson E, Bjorkholm M, Holm G, Johansson B, Nilsson B, Mellstedt M, Osterborg A. (1996) Blood clonal B-cell excess in patients with MGUS: association with malignant transformation. British Journal of Haematology, 92, 71-76.
6. Dune BGM. (1986) Staging and kinetics of multiple myeloma. Seminars in Oncology, 13, 300-309.
7. Kyle RA. (1993) Benign monoclonal gammapathy: after 20-30 years of follow-up. Mayo Clinic Proceedings, 68, 26-36.
8. Cuzick J, Cooper EM, MacLennan IC. (1985) The prognostic value of serum beta2 microglobulin compared with other presentation features in myelomatosis. British Journal of Cancer, 52, 1-6.
9. Kyle RA, Greipp PR. (1982) Idiopathic Bence Jones proteinuria. New England Journal of Medicine, 306, 564-567.
10. Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. (1992) C-reactive protein and beta2 microglobulin produce a simple and powerful myeloma staging system. Blood, 80, 733-737
11. Ballester OF, Moscinski LC, Lyman GM, Chaney JV, Saba MI, Spiers ASD, Klein C. (1994) High levels of Inerleukin -6 are associated with low tumor burder and low growth fraction in MM. Blood, 83, 1903-1908.
12. Tienhaara A, Pulkii K, Mattile K, Iyaala K, Pellinieni TT. (1994) Serum immunoreactive interleukin-6 and C-reactive protein levels in patients with MM at diagnosis. British Journal of Haematology, 86, 391-393.